Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-05-19

Opinion for Celgene Corp (CELG-Q)

Signal Price Bias Subject Owned
DON'T BUY $116.930 BULLISH US EQUITIES No

Trading at 25X price to cash flow, a bit too rich for him. The stock is up 17% over the last 12 months. The bet on this company is that you have faith in their pipeline executing on future drugs. There is much more attractive value in healthcare outside of this.

John Petrides
Managing Dir. & Portfolio Manager, Point View Wealth Management

No Comments.


You must be logged in to comment.